• Search History (Register)
  • MeSH Browser
Sort by Relevance
Search Results [15931 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Appropriate use of hand-held wireless devices in healthcare settings: guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Bivalirudin infusion following angioplasty: safety
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Rivaroxaban (Xarelto- Bayer Inc.) new Indication: pulmonary embolism
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Golimumab (Simponi - Janssen Inc.) new indication: ulcerative colitis
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Nebulizers for the methacholine challenge test: diagnostic accuracy and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Intra-aortic balloon pumps for cardiac conditions: guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Sterilization of gauze for surgical procedures: clinical effectiveness, harms, and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Personal protection for visitors to patients on airborne precautions: clinical effectiveness and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Tocilizumab (Actemra - Hoffmann-La Roche Limited) new indication: polyarticular juvenile idiopathic arthritis
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Equipment required for medication nebulization: safety and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Fall prevention strategies for adults in outpatient programs: clinical evidence and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Mobile apps for improving health: clinical evidence
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Eplerenone (Inspra - Pfizer Canada Inc.) new indication: NYHA class II heart failure
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Direct acting antivirals for chronic hepatitis C genotype 1 in select populations: emerging evidence of clinical effectiveness and safety
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Closed intensive care units: clinical and cost-effectiveness, safety, and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Re-treatment with direct acting antivirals for chronic hepatitis C genotype 1: emerging evidence of clinical effectiveness and safety
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Short-acting intramuscular olanzapine for acute agitation: clinical and cost - effectiveness and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Reprocessing of single use medical devices: effectiveness, safety, and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Aspirating versus not aspirating prior to injection of medication: comparative clinical evidence and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Providing rehabilitation services for seven days versus five days per week: clinical effectiveness and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) BMI reduction and chronic disease management: clinical evidence
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Suspended ceiling lifts: safety
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Suctioning for respiratory blockage: clinical effectiveness and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Cleaning wipes for prevention of C. difficile infection in the hospital setting: clinical effectiveness
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Fecal bacteriotherapy for adult patients with recurrent clostridium difficile infection: update of clinical, cost-effectiveness, and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Antibacterial sutures for wound closure after surgery: update on clinical effectiveness and guidelines for use
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Population-based colorectal cancer screening: guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Extracorporeal photopheresis following bone marrow transplant: clinical effectiveness
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Post-surgical surveillance for surgical site infections: guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Oral nutrition intake for the prevention of falls in older adults: clinical effectiveness and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Vitamin supplementation for hospitalized adults: clinical evidence and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Tools assessing patient-reported outcome measures in cancer patients: accuracy and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Apixaban and rivaroxaban for stroke prevention in atrial fibrillation: safety
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Conjugate pneumococcal vaccine (13-Valent) for immunocompromised populations: a review of the clinical evidence
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Bronchial thermoplasty for severe asthma: clinical and cost-effectiveness, and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Disposable surgical gowns and wrappers: clinical and cost-effectiveness, and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Loop recorders to detect atrial arrhythmias in patients post-discharge who have had a cryptogenic stroke: a review of clinical and cost-effectiveness
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Third-line pharmacotherapy for type 2 diabetes erratum
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Case management for vulnerable or homeless persons: clinical and cost-effectiveness, and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Diagnostic computed tomography angiography for adult patients: safety
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Nitroglycerin for the treatment of pulmonary edema following submersion: clinical effectiveness and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Vitamin D testing for northern populations: clinical and cost-effectiveness and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Long-term use of ranibizumab for the treatment of age-related macular degeneration: a review of the clinical and cost-effectiveness and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Alcohol with chlorhexidine hand sanitizers: clinical effectiveness and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Vancomycin-resistant enterococci isolation and screening strategies: clinical evidence and cost-effectiveness
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Mobile x-ray imaging versus fixed x-ray imaging in long-term care: clinical and cost-effectiveness
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Dutasteride and finasteride for men with benign prostatic hyperplasia: comparative clinical effectiveness and safety
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Ingenol mebutate (Picato - LEO Pharma Inc.) indication: actinic keratosis
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Ingenol mebutate (Picato LEO Pharma Inc.) indication: topical treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Ingenol mebutate (Picato LEO Pharma Inc.) indication: topical treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Ketamine for adult patients who have suffered painful and traumatic injuries: a Review of Clinical Effectiveness, Cost-Effectiveness, Safety and Guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Plasma Vaporization of the Prostate for Treatment of Benign Prostatic Hypertrophy: A review of clinical and cost-effectiveness, and safety
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Computed tomography scanners for patients in rural or remote locations: clinical and cost-effectiveness
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) The ABCD2 scoring system for transient ischemic attacks: a review of the diagnostic accuracy and predictive value
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Fall risk assessment in adult patients: comparative evidence and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Endoscopic ultrasound for the diagnosis of disease and staging of cancers in adult patients with gastroenterological or oncological disease: guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Mobilization of adult inpatients in hospitals or long-term/chronic care facilities: benefits and harms, safety, and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Hepatitis C polymorphism testing: a review of the clinical evidence
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Platelet rich plasma lumbar disc injections for lower back pain: clinical effectiveness, safety, and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Oncotype DX in women and men with ER-positive, HER2-negative early stage breast cancer who are lymph node negative: a review of clinical effectiveness and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Diabetes care for indigenous populations: a review of the clinical evidence and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Bolused (vice infused) tranexamic acid in adults experiencing hemorrhagic shock: safety, patient benefits, and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Ocriplasmin (Jetrea - Alcon Canada Inc.) indication: symptomatic vitreomacular adhesion
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Ocriplasmin (Jetrea - Alcon Canada Inc.) indication: symptomatic vitreomacular adhesion
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Ocriplasmin (Jetrea - Alcon Canada Inc.) indication: symptomatic vitreomacular adhesion
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Somatropin (Genotropin - Pfizer Canada Inc.) indication: Turner syndrome
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: Turner syndrome
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: Turner syndrome
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: long-term treatment of children who have growth failure due to an inadequate secretion of endogenous growth hormone
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: long-term treatment of children who have growth failure due to an inadequate secretion of endogenous growth hormone
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Somatropin (Genotropin - Pfizer Canada Inc.) indication: long-term treatment of children who have growth failure due to an inadequate secretion of endogenous growth hormone
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: growth hormone deficiency in adults
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: growth hormone deficiency in adults
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Lyophilized plasma for the treatment of adults with hemorrhagic shock: clinical and cost-effectiveness, safety, and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Suboxone versus methadone for the detoxification of patients addicted to prescription opioids: a review of comparative clinical effectiveness, safety, and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Viscosupplementation for the treatment of osteoarthritis of the knee: clinical effectiveness and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) iTClamp for controlling compressible gemorrhage in adults: clinical effectiveness, cost-effectiveness, and safety
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Nutritional supplementation for patients with cancer: a review of the clinical effectiveness and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Interventions for non-elderly patients who are high users of ambulatory and emergency medical services: clinical and cost-effectiveness
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Non-invasive prenatal testing: a review of the cost effectiveness and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Trientine for treatment of Wilson's disease: clinical and cost-effectiveness, and safety
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Magnetic resonance spectroscopic imaging for prostate disease detection: clinical and cost-effectiveness, and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Next generation DNA sequencing: a review of the cost effectiveness and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Icatibant for patients with type III hereditary angioedema: a review of clinical effectiveness and harms
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Single-use medical devices reprocessed by third party/licenced reprocessors: patient benefits and harms, cost-effectiveness, and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Drug interventions for chronic non-cancer pain: guidelines and recommendations
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Non-drug interventions for chronic non-cancer pain: guidelines and recommendations
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Flushing intravenous tubing post administration of medications: clinical evidence and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Paracentesis for the removal of peritoneal fluid: guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Positron emission tomography in neurology and cardiology: a review of guidelines and recommendations
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Buprenorphine/naloxone (Suboxone) film versus buprenorphine/naloxone tablets for the treatment of opioid addiction: comparative safety
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Oncotype DX in women and men with ER-positive HER2-negative early stage breast cancer Who are lymph node-positive: a review of clinical effectiveness and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Compressible non-articulating disc prostheses in adult patients with degenerative disc disease: clinical effectiveness, safety, cost-effectiveness, and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Smart infusion pump use in hospitalized patients: clinical safety and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Intranasal versus intravenous administration of anxiolytic or analgesic medications: comparative clinical effectiveness
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Intensivist response time to a closed intensive care unit: patient benefits and harms and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) TECNIS® or Acrysof® soft intraocular lenses for patients undergoing cataract surgery: benefits and harms, clinical effectiveness, cost-effectiveness, and guidelines